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Among multimodality treatments for acromegaly, the goals of surgical intervention are to balance maximal tumor resection
while preserving normal pituitary function and maintaining patient safety. The resection of growth hormone-(GH-) secreting
pituitary adenomas in the hands of experienced surgeons results in hormonal remission in 50–70% of patients. Acromegalic
patients often have medical comorbidities and anatomical variations complicating anesthesia and surgical management. Despite
these challenges, complications such as CSF leak or new hypopituitarism following surgery remain uncommon. Over the past
decade, endoscopic approaches to pituitary tumors have improved visualization and facilitated identiﬁcation of additional tumor
using angled telescopes. Patients with persistent acromegaly following surgery require continued medical and/or radiation-based
interventions. The adjunctive use of stereotactic radiosurgery oﬀers hormonal remission in 40–50% of patients. In this article, the
current preoperative evaluation, indications for surgery, surgical approaches, role of radiosurgery, complications, and remission
criteria following operative resection of GH adenomas are reviewed.
1.Introduction
Acromegaly is a life-threatening disorder resulting from
excessive growth hormone (GH) secretion, occurring almost
exclusively secondary to pituitary adenomas. Although other
causesrarelyexist, pituitary adenomas are the most common
culprit of this systemic condition that frequently leads to
hypertension, cardiac disease, diabetes, pulmonary disor-
ders, and associated malignancies [1]. The annual incidence
of acromegaly has been calculated to be 3-4 cases per 1
millionpeople,withaprevalenceof40–60permillionpeople
[2, 3]. Because of its insidious development and the slow
progression of clinical manifestations, acromegaly frequently
remains undiagnosed for many years. Moreover, on account
of the common delay in diagnosing GH adenomas, the
majority are macroadenomas (>10mm) at the time of
diagnosis.
Prompt treatment should be initiated for most patients
with acromegaly, as the mortality rate for uncontrolled
disease is 2–4 times higher than that of the general pop-
ulation [4–6]. Cardiovascular disease comprises 60% of
acromegaly-related deaths, with the remaining 25% and
15% accounted for by respiratory disease, and malignancies,
respectively [7]. Speciﬁcally, lung and bowel cancers account
for almost 70% of all neoplasms, and cancer mortality is
4.6-fold-higher in acromegalic men than in the normal
male population. The overall treatment goal in patients with
acromegaly is to achieve normalization of age, and sex-
speciﬁc serum IGF-1 levels, as this may reverse the increased
mortality rate associated with this disease. One of the most
eﬀectiveandrapidwaysofaccomplishingthisgoal,andoften
the preferred initial treatment, is via surgical intervention.
When possible, total resection of the tumor mass and
subsequent normalization of serum IGF-1 levels often leads2 International Journal of Endocrinology
to reversal of associated symptoms (including headache and
visual impairment), alleviation of comorbidities such as
hypertension and endocrine abnormalities, and changes in
some of the somatic features of the disease [8, 9].
While surgery is at the forefront of the treatment
paradigm, a major role for medical management still exists
in patients with acromegaly. Medications for acromegaly
are typically indicated for patients that are not surgical
candidates or do not wish to have surgery, following subtotal
tumor resection, and for patients with persistent elevations
in GH and IGF-1 levels that are awaiting the eﬀectiveness of
radiation-based treatments. Medical management may also
be indicated in patients with large GH-secreting macroade-
nomas that are not likely to be cured by surgery, in which a
decision to forego an attempt at surgical debulking is made.
First-linemedicaltherapyforacromegalyfrequentlyincludes
somatostatin analogs, such as octreotide or lanreotide.
Pegvisomant, the newest medical treatment available for GH
adenomas, blocks the hormonal action of GH at the level of
GH receptors in the liver and has been shown to normalize
IGF-1 in 97% of patients after one year of administration
[3]. Despite their poor eﬃcacy and side eﬀect proﬁles,
dopamine agonists medications, such as bromocriptine and
cabergoline, have been shown to normalize IGF-1 in a
minority of patients [3, 10, 11].
2.PreoperativeEvaluation
The diagnosis of acromegaly is based on the demonstration
of high circulating levels of GH and IGF-I, with the latter
beingthecurrentgoldstandardfordiagnosingthedisease.In
order to exclude acromegaly as a diagnosis, a single random
GH level lower than 0.4µg/L and an IGF-I value in the age-
and sex-matched normal range must be met. In uncertain
cases (i.e., when these two criteria are not met for exclusion),
a 75g oral glucose test (OGTT) should be conducted. The
lack of serum GH suppressibility below 1µg/L (0.3µg/L
according to recent reports) within two hours after an oral
glucose load will conﬁrm the diagnosis [12].
In greater than 90% of patients, acromegaly is caused by
a pituitary adenoma [10, 13, 14]. Other causes of acromegaly
include tumors of the pancreas, lungs, and adrenal glands.
Magnetic resonance imaging (MRI) of the sellar region,
with and without gadolinium contrast administration, is the
gold standard imaging study for diagnosis and preoperative
assessment of these pituitary adenomas. Speciﬁcally, infor-
mation regarding tumor size and location can have tremen-
dous value during and after surgical intervention. Moreover,
intracavernous extension (ICE), which often hinders the
complete removal of pituitary adenomas, should be assessed.
GH adenomas have a demonstrated propensity to invade the
infrasellar region, often growing through the sellar dura and
bony ﬂoor into the sphenoid sinus [14]. If the tumor extends
into the suprasellar region, an ophthalmological examina-
tion to evaluate for visual ﬁeld defects should be acquired
prior to treatment. While the utility of MRI in diagnosing
the primary cause of acromegaly cannot be overstated, it
should be noted that the ability to predict surgical outcomes
Table 1: Preoperative factors correlating with surgical outcomes in
acromegaly [7, 15].
Favorable outcomes Unfavorable outcomes
Older age Younger age
Preoperative GH level of
<45ng/mL
Preoperative GH level of
>45ng/mL
Noninvasive tumor Invasive Tumor
Micoradenoma (≤10mm) Macroadenoma (>10mm)
Densely granulated GH adenoma Acidophil stem cell tumor
on the basis of preoperative pituitary MRI is still being
investigated. Nevertheless, recent studies have shown that
preoperative MRI is very useful for the prediction of certain
surgical results. For example, cure is much less likely in
patients harboring tumors greater than 15mm in diameter,
those with suprasellar extension above the optic chiasm, and
in the setting of extensive intracavernous extension [13].
Table 1 providesotherpreoperativepredictorsthathavebeen
proposed. It should be noted that because patients with
acromegalyusuallyhaveatypicalvascularandbonyanatomy,
additional imaging (i.e., CT or CT angiography) may be
necessary to plan the proper approach, assess the degree of
bony disease, and avoid vascular injuries [14].
3. Indications for Surgery
Surgery is the ﬁrst line treatment for most patients
with acromegaly. Indications for surgery include active
acromegaly with an appropriate surgical target, visual loss,
andotherformsofmasseﬀect,pituitarytumorapoplexy,and
refractory or progressive disease despite treatment attempts
using other therapies. Some contraindications to surgery
include advanced age, general debility, or other commonly
occurring medical comorbidities (i.e., cardiovascular or
pulmonary disease) [9]. Preoperative evaluation in patients
with acromegaly should also include a detailed assessment
of clinical features (i.e., enlargement of facial features,
cutaneous changes, arthropathies, changes in cardiovascular
system,andsignsandsymptomsofhypopituitarism).Airway
evaluation by an anesthesiologist is often required, as many
acromegalic patients have signiﬁcant tongue and airway
edema that may require specialized intubation.
4.SurgicalApproach
Surgical approaches in patients with acromegaly have
evolved dramatically since Drs. Caton and Paul ﬁrst
attempted to resect a pituitary tumor in 1893 [9]. A major
driving force behind the evolution of these techniques has
been improvement in surgical optics and instrumentation,
which have fueled the trend towards progressive minimal-
ization. Generally speaking, access to the pituitary region
involves either an open craniotomy or a transsphenoidal
approach. The transphenoidal approach can be completed in
two distinct fashions: via a microscope or with the assistance
of an endoscope.International Journal of Endocrinology 3
5. Transsphenoidal Surgery
Transsphenoidal surgery, speciﬁcally transsphenoidal micro-
surgical adenectomy, has become the primary surgical
approach for treating pituitary adenomas over the past
several decades [9, 15, 16]. The other major option for
large tumors with extensive suprasellar or lateral extension
is an open craniotomy (see below). Certain factors that
must be taken into account when deciding on a particular
surgical approach include the anatomy of the sinuses and
pituitary region (i.e., size and morphology of the sella, pneu-
matization of air sinuses, etc.), the surgeon’s experience,
and extent of tumor burden [9, 17]. With regard to the
transsphenoidal approach, an assessment of the pattern
of extrasellar extension on preoperative MR images is
essential prior to resection of pituitary adenomas, in order
to delineate which regions pose the greatest limitation for
tumor resection and are likely to retain residual tumor
[14, 18].
6. Endoscopic Transsphenoidal Surgery
Minimally invasive techniques have been at the forefront
of approaches to the pituitary gland. In recent years,
the use of endoscopes has become commonplace during
transsphenoidal pituitary adenoma resection. Pure endo-
scopic approaches oﬀer the beneﬁts of improved illumi-
nation and magniﬁcation, panoramic visualization, angled
endoscopes to “look around corners” for residual tumor,
and obviate the need for nasal retractors or nasal packing
in most cases. Furthermore, the use of endoscopes oﬀers a
widerrangeoftargetsalongthearcoftheskullbase,fromthe
frontalsinusesanteriorlyandsuperiorlytothecraniocervical
junction posteriorly and inferiorly.
7.Craniotomy
For GH adenomas that have suprasellar extension or are
mainly localized outside of the sella, transcranial approaches
are often necessary for improved visualization of the pitu-
itary tumor. With a frontotemporal craniotomy, once the
frontal lobes have been carefully retracted, the surgeon can
directly see the optic nerves or chiasm and any extension
of the pituitary tumor into the anterior fossa, middle fossa,
or suprasellar region [9, 19]. A supraorbital “eyebrow”
keyhole craniotomy may also be utilized to approach the
suprasellar region and optic apparatus and can also be used
in conjunction with the endoscope. Other indications for
transcranial approaches have traditionally included a small
sella turcica with a large extrasellar component, unfavorable
or nonpneumatized parasellar nasal sinuses, coexisting ICA
or ACA aneurysm or other vascular anomalies, or ﬁrm or
ﬁbrous pituitary adenomas (identiﬁed during a previous
procedure). It should be noted, however, that as techni-
cal advances are made in the endoscopic transsphenoidal
approach, the limitations and contraindications associated
with transsphenoidal surgery continue to diminish [19].
8.SurgicalResults
8.1. Surgical Outcomes. Although transsphenoidal cran-
iotomy (TSC) is considered the gold standard intervention
for the treatment of acromegaly, it is imperative that the
goal of treatment—the restoration of a normal GH secretion
proﬁle and normalization of serum IGF-1—not be over-
looked [13]. In the majority of cases, surgery provides long-
term remission in 70–88% of patients with microadenomas
and 50–61% of patients with macroadenomas. The ability to
achieve hormonal remission following TSC is often limited
by tumor size (i.e., macroadenomas ≥ 10mm diameter), the
degree of extrasellar extension (particularly lateral into the
cavernous sinuses), and high preoperative serum GH con-
centrations (≥45ng/mL)[7,16,20].Lawsetal.characterized
microscopic invasiveness of the tumor as a factor that is also
associated with outcomes following transsphenoidal surgery
for acromegaly. In their analysis, hormonal recurrence after
10-year follow-up occurred in 8–10% of patients and was
more likely in tumors that invaded the parasellar dura or
bone [15].
8.1.1. Risks and Complications Associated with Surgical
Approaches for Acromegaly. Aside from the periopera-
tive medical risks inherent to patients with acromegaly,
many risks associated with transsphenoidal operations for
acromegaly may be heightened on account of the anatomical
deviationsoccurringfrequentlyinthispopulation.Common
factors that may aﬀect the intraoperative plan include
airway/laryngeal edema, cardiopulmonary dysfunction, and
venous congestion. During the approach itself, the initial
visualization can be limited by mucosal edema/redundant
tissue, hypertrophic nasal turbinates, and thickened nasal
bones (i.e., the sphenoid rostrum and vomer). In addition,
thickened sphenoid septa and mucosa may lead to restricted
workspace within the sinus and excessive mucosal bleeding.
Lastly, patients with longstanding acromegaly often have
enlargement and tortuosity of the internal carotid arteries
and occasionally have aneurismal formations [9, 14, 15].
Therefore, it is important to assess the course of the ICA
within the parasellar nasal and cavernous sinuses prior to
selecting a surgical approach.
Complications that are associated with transcranial
approaches for GH-denomas include hemorrhage, infection,
or stroke secondary to brain retraction/ischemia. In acrome-
galic patients, the frontal sinuses are often unusually large,
and violation ofa frontal sinus during a cranial approachcan
lead to a cerebrospinal ﬂuid leak and subsequent meningitis
if not properly identiﬁed and repaired during surgery. Close
scrutinyofpreoperativeimagingstudiesandimplementation
of various intraoperative maneuvers may optimize the safety
proﬁles associated with any surgical procedure for GH
adenomas [9].
Despite the prevalence of medical comorbidities in this
population, overall morbidity rates associated with the
surgical management of acromegaly remain extremely low,
and mortality has been reported in less than 0.5% of patients
treated in high-volume centers [3, 15, 19, 21]. The most
common postoperative patient complaints are usually due4 International Journal of Endocrinology
to sinonasal causes (approx. 60% in one recent study) [22],
with nasal congestion (42%), alteration in taste or smell
(30%), sinusitis (30%), and epistaxis (6.7%) occurring most
frequently [22]. Cerebrospinal ﬂuid leakage is the next most
common complication and has been reported to occur in 1–
5% of cases [3, 10]. Transient endocrine disturbances such as
diabetesinsipidus(DI)havebeennotedinapproximately3%
of cases. Moreover, DI develops more commonly following
transcranial approaches than transsphenoidal approaches,
typically as a result of manipulation of the pituitary stalk or
hypothalamus. Permanent DI is rare, developing in 1-2% of
patients following surgery. The syndrome of inappropriate
antidiuretic hormone hypersecretion (SIADH) resulting in
hyponatremiahasbeenshowntooccurin8%ofpatientsand
typically occurs in a delayed fashion approximately one week
following the operation [13, 23].
Although visual loss and hypopituitarism may result
from tumors causing acromegaly, they can also result from
iatrogenic injury during surgical tumor resection. Both
hypopituitarism and visual loss occur much more frequently
in patients with macroadenomas [6, 24]. The evaluation
of pituitary function and visual ﬁelds are important in
the preoperative assessment of patients with acromegaly
and may serve as baseline studies from which to identify
improvementsorcomplicationsoccurringfollowingsurgery.
Visual loss has been reported in 5% of patients following
transsphenoidal surgery, while new hypopituitarism may
develop in 10–20% of patients [6, 25]. Vascular injury,
speciﬁcally to the internal carotid arteries, is one of the
most serious complications of surgical intervention for
acromegaly and may result in a pseudoaneurysm, stroke,
or death. The incidence of carotid artery injury during
transsphenoidal surgery, however, is less than 0.5%. Post-
operative hemorrhage into the tumor resection cavity can
lead to worsening pressure on the optic nerves or chiasm
and possibly visual loss, is associated with subtotal tumor
resection, and mandates urgent surgical evacuation.
9. MultimodalTherapy and
the Role of Radiosurgery
Multiple radiation-based treatment strategies have been
described for residual or recurrent pituitary adenomas.
Nearly 75% of GH producing tumors are macroadenomas
at the time of diagnosis, and often invade the surrounding
dura and bone, making complete surgical resection nearly
impossible without compromising patient safety [26]. Fol-
lowing microsurgical resection, 10–50% of patients will have
persistent elevations in GH and/or IGF-1 levels [9, 27, 28].
Furthermore, the recurrence rate following initial hormonal
remission is 8–20% in patients with acromegaly [15, 27, 29].
In GH-producing tumors following subtotal surgical resec-
tion or disease recurrence, radiation treatment, and medical
therapy can be used either separately, or in conjunction,
as adjunctive modalities to achieve endocrine remission
and control tumor growth. The beneﬁts of radiation-based
treatments, such as external beam therapy and radiosurgery,
must always be weighed against inherent risks such as new
hypopituitarism, visual loss, and cranial nerve deﬁcits.
Fractionated external radiotherapy has been described
in the treatment of somatotrophic adenomas with varied
success rates (5–74% hormonal remission), a long latency to
functional response (5–15 years), and high rates of pituitary
dysfunction (50–80%) [28, 38, 39]. The relatively high rates
of adverse eﬀects associated with radiotherapy have limited
its use in recent years, with treatment practices shifting
towards radiosurgery in the majority of major treatment
centers. Stereotactic radiosurgery was ﬁrst described by
Lars Lesksel in 1951 and has been shown to be eﬀective
in the treatment of a variety of intracranial tumors [40].
Radiosurgery uses multiple low energy radiation beams
designed to converge on a stereotactic target, resulting in
high-dose radiation speciﬁc to the target with a sharp
falloﬀ in exposure outside the target. The radiation may be
deliveredasphotonsinGammaKnifeSurgery(GKS)andlin-
ear particle accelerator-(LINAC-) based radiosurgery (e.g.,
CyberKnife), or as charged particles in the case of proton-
beam radiosurgery. Although treatment of acromegaly has
been described with LINAC and proton-beam radiosurgery,
few studies with small numbers of patients have limited
signiﬁcant evaluation of their eﬀectiveness as compared to
GKS, which many studies have evaluated [10, 26–28, 30, 32,
34, 35, 41–47]. GKS consists of a frame-based single session
treatment, with mean marginal radiation doses for growth
hormone adenomas typically ranging between 14–34Gy to
the 50% isodose line [48].
G K Sh a sb e e nf o u n dt ob ee ﬀective in the treatment of
acromegaly in multiple large cohorts [26, 27, 30, 32, 35–
37, 43, 46, 47, 49]. Among published case series of GH
adenomas treated with radiosurgery, tumor control (stable
or decreased tumor volume) was achieved in 97% of patients
[48]. Radiosurgery has been less successful in achieving
endocrinological remission, deﬁned as normalization of age-
and sex-appropriate IGF-1 and GH levels, with hormonal
remission rates among larger case series being 17–96% [26,
27, 30–32, 34–37, 43, 46, 49]. This large variation among
studies reporting results of radiosurgery for acromegaly
may be attributed to diﬀerences in hormonal remission
criteria (threshold of GH or IGF-1 levels), treatment plans
(radiation dose), and length of followup time. According
to a meta-analysis of 970 patients in a recent review,
endocrine remission was achieved in 48–53% of patients
after radiosurgery, with an overall disease control rate (with
or without ongoing medical therapy) of 73% [50]. Jagan-
nathan et al. reported a median time to remission of 29.8
months following GKS [26, 51]. Reported factors associated
with postradiosurgical endocrine remission include higher
prescribed radiation dose, lower preradiosurgery GH and
IGF-1 levels, and holding hormone suppressive medications
prior to radiosurgery [27, 30, 37, 43, 46].
It has been reported that some medications used to treat
acromegaly, especially somatostatin-analogos, may make
tumors less susceptible to radiosurgery by altering tumor
metabolism dynamics and the cell cycle [26, 46, 51, 52].
Pollock et al. described a series of 31 patients treated with
octreotide at the time of radiosurgery, in which the timeInternational Journal of Endocrinology 5
Table 2: Radiosurgery case series including greater than 50 acromegalic patients.
Number of
Patients
Type of
radiosurgery
Mean marginal
dose (Gy)
Acromegaly
remission (%)
Mean followup
(months)
Pituitary hormone
deﬁciency (%)
Losa et al. 2008
[30] 83 GK 25 (goal) 60.2 69 8.5
Jagannathan et al.
2008 [26] 95 GK 22 53 57 34
Vik-Mo et al. 2007
[31] 61 GK 26.5 17 66 13
Voges et al.2006
[32] 64 LINAC 15.3∗ 37.5 81.9∗ 12.3∗
Jezkova 2006 [33] 96 GK 32 44 53.7 27
Castinetti et al.
2005 [34] 82 GK 26.3 17 49.5 17
Kobayashi et al.
2005 [35] 67 GK 18.9 16.7 63.3 14.6
Jane et al. 2003
[36] 64 GK 15∗ 36 NR 28
Zhang et al. 2000
[37] 68 GK 31.3 96 >24 NR
∗represents all adenomas in study not speciﬁc to growth hormone pituitary adenomas.
NR = value not recorded in study.
to remission was signiﬁcantly longer than in patients not
receiving octreotide at the time of treatment [46]. Pollock
et al. reported that holding growth hormone suppressive
medications at the time of GKS correlated with biochemical
remission [46]. This has led some groups to recommend
holding somatostatin-analogs for at least a month prior
to radiosurgery, based on research showing long acting
somatostatin-analogs such as Sandostatin LAR may exert a
suppressive eﬀect on GH release for 8–12 weeks [46, 52, 53].
The optimal timing for withholding suppressive medications
is still under investigation, but most groups recommending
this practice suggest a time of 4–8 weeks prior to GKS.
Although, in general, radiosurgical treatments oﬀer
safe treatment proﬁles with few side eﬀects, complications
associated with treatment do occur and must be considered
seriously prior to treatment. Common complications of
stereotactic radiosurgery include pituitary hormone deﬁ-
ciency, visual disturbances, and cranial nerve deﬁcits. New
pituitary hormone deﬁciency is the most frequently reported
complication of radiosurgery for parasellar tumors, aﬀecting
2–47%ofpatients[26,27,30–32,34–37,43,46,47].Pituitary
hormone deﬁciency tends to occur in a delayed fashion and
is usually ﬁrst observed at 1.5–5 years after radiosurgery
[26, 52]. Thus, in studies with longer followup, the rate
of pituitary dysfunction tends to increase. Larger tumor
volume, speciﬁcally greater than 4cm3, has been correlated
with a higher incidence of hormone deﬁciency after GKS
[52, 54]. This is likely related to the larger treatment volume
required in these cases. Therefore, a common paradigm
for the treatment of pituitary adenomas consists of tumor
debulkingpriortoGKS[52].Ingeneral,visualcomplications
occur rarely following GKS, with the majority of series
having no cases of visual loss reported. In those cohorts
that did contain visual complications, the reported rate
ranged between 1–11% [26, 32, 34, 35, 37]. Strategies to
minimize visual loss associated with GKS include limiting
its use to lesions at least 3mm from the optic nerves or
chiasm [45]. For those tumors <3m mf r o mo p t i cs t r u c t u r e s ,
multisessionframelessradiosurgery(i.e.,Cyberknife)maybe
a safe alternative [55]. Cranial nerve deﬁcits were reported
in only three of 45 case series, according to a recent
review [48]. Other rarely reported complications of radio-
surgery include headache, trigeminal neuralgia, temporal
lobe epilepsy, radiation necrosis, and carotid artery stenosis
[48].Complicationratesmaybeskewedbythefactthatmany
patients underwent craniotomies or radiotherapy prior to
radiosurgery. Multiple groups have noted that postradio-
surgical complications were more common in patients who
previously received conventional radiotherapy [26, 46].
In summary, radiosurgery oﬀers long-term tumor con-
trol in greater than 90% of patients with acromegaly,
endocrine remission in approximately 50% of patients, and
relatively low complication rates. Radiosurgery appears to
have a shorter latency until functional response, and fewer
side eﬀects, than radiation therapy. In most major treatment
centers, radiosurgery has replaced conventional external
beamradiationtherapyasthepreferredadjunctivetreatment
in patients whose acromegaly is not controlled with surgery
and GH-suppressive medications. Because of the latency in
functional eﬃcacy, risk of delayed recurrence, and small
potential for adverse eﬀects, close long-term followup is
recommended in all patients who have received radiation-
based treatments. Table 2 summarizes the ﬁndings of various
radiosurgical case series.
10. Postoperative Remission Criteria
While the goal treatment of acromegaly is the restoration of
a normal pulsatile GH secretion pattern and normalization6 International Journal of Endocrinology
of serum IGF-1, the actual deﬁnition of hormonal is ever-
changing. In the last decade, remission rates have been in
evolution as hormone assays have become more sensitive [1,
29]. The Consensus on Criteria for Cure of Acromegaly 2010
deﬁned biochemical cure to be (at 6 weeks postoperative
followup visit) a random GH measurement of 2.5µg/liter
or less, glucose-suppressed (nadir) GH less than 1.0µg/liter,
and a normal sex- and age-matched IGF-1 level [12, 19,
29]. Krieger et al. found that a fasting morning GH level
lower than 2µg/liter measured at postoperative day 1 was an
important predictor of remission. This study concluded that
although IGF-1 is an indicator of long-term disease control,
a reliable assay for aiding in postoperative management of
these patients is an early postoperative GH level.
11. Conclusions
Acromegaly is a life-threatening disease often requiring
chronic interdisciplinary care by a skilled team of endocri-
nologists, neurosurgeons, ophthalmologists, and radiation
oncologists, among others. The eﬃcacy of transsphenoidal
surgery to rapidly reduce GH hypersecretion in the treat-
ment of acromegaly has been documented extensively.
Although transsphenoidal surgery is often the preferred
initial treatment for this disorder, patients nevertheless
require appropriate long-term hormonal and imaging follow
up to identify delayed recurrence and guide adjunctive
radiation-based and medical treatment. In recent years, the
advent of radiosurgery has provided another alternative
in the overall treatment of patients with acromegaly. It is
of utmost importance as a clinician to understand that
the systemic eﬀects of chronic GH excess are reversible if
complete surgical remission and long-term normalization of
GH levels can be achieved via multimodal surgical, medical,
and radiosurgical therapy.
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